Radiologists review thousands of images a day. The hope is that artificial intelligence (AI) applications will become useful soon to verify diagnoses, prioritize queued images and even to offer a level of detection and measurement that aren't feasible for humans. One of the latest efforts on this front is by researchers at the University of California at San Francisco (UCSF) and the University of California at Berkeley.
Researchers at the Abramson Cancer Center at the University of Pennsylvania have developed an algorithm to better personalize immunotherapy treatment. The algorithm works by examining neoantigen quality, not just their quantity. Neoantigens are proteins that are the result of genetic mutations in a tumor.
PERTH, Australia – Following stunning interim clinical results for its Celgro nerve regeneration treatment in quadriplegic patients, regenerative medicine company Orthocell Ltd. will focus all its efforts on gaining quick U.S. FDA approval based on the early results.
LONDON – A paper that raised concerns for the future health of Lulu and Nana, the world's first gene-edited babies, has been fully retracted at the request of the authors, after they failed to identify a problem in data from the U.K. Biobank on which their analysis was based. The study published in Nature Medicine in June, concluded the edits the twin girls are purported to have in their CCR5 chemokine receptor gene is associated with a 21% increase in mortality in middle and old age.
Synthetic biology is seeing rapid advances, but the medical applications have thus far remained largely elusive. But now researchers from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard Medical School (HMS) have developed a tool that can track specific populations of bacteria in the gut of living organisms and document population changes over time.
Australian researchers have developed the first potent new small-molecule inhibitors capable of blocking the activation of apoptotic cell death before it causes damage to mitochondria, they reported in a study published in the Oct. 7, 2019, issue of Nature Chemical Biology. Those first-in-class inhibitors will be useful tools for evaluating the mechanisms underlying apoptosis, assessing the impact of the pharmacological blockade of apoptosis in experimental models and potentially have multiple clinical indications.
There's a yin and yang to neoantigens, Alberto Bardelli told the audience at the 2019 annual conference of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, last month. They contribute to tumorigenesis, resistance and tumor heterogeneity. But they are also often specific to tumor cells but not normal cells and "some," he said, "are actionable targets."
RSS